Shaping the future of drug development
Improving the design and implementation
of clinical trials
Powering your trial to success
Comprehensive software solutions for
designing and running your trials
SOFTWARE SOLUTIONS
Experience   Expertise   Innovation
Succeed in your clinical development with
our design and implementation advice
STRATEGIC CONSULTING
Getting it right the first time
Providing expertise and experience to
get you the best information from your trial
CLINICAL RESEARCH SERVICES

 SOFTWARE SOLUTIONS

Rigorously tested and continuously validated in practice, Cytel software is used at thousands of pharmaceutical, biotech, medical device companies, and leading independent research institutes.

 STRATEGIC CONSULTING

Cytel’s cutting-edge trial design and implementation expertise, with a specialty in adaptive trials, is helping sponsor companies of all sizes to increase success rates in clinical development.

 CLINICAL RESEARCH SERVICES

For proven product development knowledge and experience, rely on our global multi-disciplinary teams – biostatisticians, operations experts, data managers, programmers and medical writers.


Latest News & Events

Bay Area Symposium: Clinical Trial Statistical Innovations, Feb 26th

Cytel and the ASA San Francisco Chapter present forum on new statistical approaches transforming drug development. Experts speak on designing adaptive trials strategically aligned with development goals.

SCOPE February 24: Enrollment Planning and Patient Recruitment

Will your trial enroll the needed patients in time? Cytel unveils simulation-based trial enrollment forecasting advances. Go to the Cytel booth for software demos and further information.

March 24 - 26, Boston Cyrus Mehta Reveals Lessons Learned from Adaptive Trials in Oncology

“Adaptive Oncology Trials with Time to Event Endpoints” by Cytel President & Co-Fonder Cyrus Mehta chronicles the impact of adaptive approaches in oncology clinical development.

What Clients Say

"Cytel’s work on the trial design, simulations and FDA discussions were instrumental in obtaining the regulatory acceptance for our proposed, ground-breaking methodology.

Implementation was smoother thanks to their experience with adaptive population enrichment strategies."

--Simona Skerjanec, VP Medical Science
The Medicines Company

"Cytel’s innovative, yet practical adaptive design provided multiple favorable scenarios allowing us stage the Phase 3 VALOR leukemia treatment trial based on sample size re-estimation.

Difficult to imagine our going forward with traditional clinical trial methods alone."

--Steven B. Ketchum, VP Research and Development
Sunesis Pharmaceuticals

"Working with Cytel allowed our team to move forward from research to reality swiftly.

We now have the tools to guide our innovative trial decision-making much more efficiently and knowledgeably."

--Joe Heyes, VP
Early Stage Biostatistics Merck

"To my knowledge, Fulyzaq® is the very first approved treatment following a two-stage adaptive pivotal study.

There’s no question that without Cytel we wouldn’t have achieved that. You have been very service-oriented and responsive throughout."

--Dr. Scott Harris, CMO
Napo Pharmaceuticals

"We learned controlling critical operational variables with ongoing collaboration – especially between data managers and statisticians – was crucial to trial success.

We even saved 20% by outsourcing the key data analytics, medical writing and submission preparation functions with Cytel."

--Dr. Patrice Rioux, VP, CMO
Raptor Pharmaceuticals

"The Cytel team understood precisely what we needed, and delivered quality work within a very demanding timeframe.

They did it right the first time. As a result, we provided the FDA-requested safety reports without impacting our development timelines."

--Sylvain Nicolas, Global Head Biostatistics Phase 1 Studies
Sanofi


Explore Our Products
Case Studies

Copyright © 2014 Cytel. All rights reserved